Barclays analyst Christine Cho maintains Array Technologies (NASDAQ:ARRY) with a Overweight and raises the price target from $20 to $22.
Expert Ratings for Intra-Cellular Therapies
Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…